Travere Therapeutics (TVTX) – FILSPARI Run-Up, Record Sales & New FSGS PDUFA April 13, 2026

1. What changed on TVTX and why traders care again

Travere Therapeutics has just gone through a classic “headline shock, fundamentals still intact” sequence. The U.S. Food and Drug Administration extended the review timeline for the supplemental New Drug Application (sNDA) of FILSPARI in FSGS and pushed the PDUFA target action date from January 13 to April 13, 2026. The stock initially sold off hard as algos reacted to the word “delay”. (FSGS PDUFA PR)

The details, however, are much more nuanced. The extension follows Travere’s submission of additional analyses to further characterise the clinical benefit of FILSPARI in FSGS, which the FDA classified as a Major Amendment. By rule, that classification automatically extends the review clock. The 8-K filed with the SEC does not mention any new safety or manufacturing concerns, and FILSPARI remains fully approved and commercial in IgAN in both the U.S. and Europe. (8-K SEC)

For traders, this is closer to a timing reset than a thesis reset: the binary event is still there, just three months further out.

2. FILSPARI: from first full year to rare-disease cash engine

Main sources: FY 2024 results, 2025 corporate updates, and Q3 2025 8-K / PR.

FILSPARI is no longer an “early launch” story. For 2024, Travere reported $132.2M in FILSPARI net product sales, the first full year of commercialisation. (FY 2024 results PR) In 2025, the ramp accelerated sharply: according to the January 2026 corporate update, preliminary U.S. net product sales of FILSPARI reached about $322M, while total U.S. net product sales across the portfolio are expected around $410M. (corporate update)

The Q4 2025 numbers are even more telling: the company expects approximately $103M of U.S. FILSPARI net product sales in the quarter, a 108% year-over-year growth vs Q4 2024, supported by an all-time-high 908 new patient start forms. The drug is consolidating its position as a foundational therapy in IgAN, helped by KDIGO guidelines and streamlined REMS monitoring. (SA recap of corporate update)

3. April 13, 2026 PDUFA – trading calendar and run-up logic

The new PDUFA target action date for the FSGS sNDA is now set for April 13, 2026. (FSGS PDUFA PR) The extension reflects the FDA’s decision to treat the additional data package as a Major Amendment. The 8-K is explicit that the extension follows the submission of further analyses to characterise clinical benefit; it does not introduce new safety or CMC concerns. (8-K SEC)

For run-up traders, three elements stand out:

• the binary event is still alive, just pushed out by roughly one quarter;
• the first wave of selling has already flushed a good part of the weak-hand holder base;
• underneath, FILSPARI’s IgAN business and the cash profile look better than a few months ago.

This is the exact pattern many catalyst-driven traders like: nasty headline, sell-off, then a period in which the company keeps printing solid numbers while the calendar quietly moves closer to the new decision date.

4. Retail sentiment – from panic to chart-watching

5. Trader’s angle – what really matters into Q1/Q2 2026

From a trader’s perspective, the map for TVTX over the next few months is fairly clear:

• Fundamental backbone: a rare-disease launch that is already generating hundreds of millions in annual sales, with a cleaned-up balance sheet and credible cash position.
• Binary catalyst: the April 13 FSGS PDUFA, which could unlock a second leg of growth if positive or force a reset of medium-term expectations if negative.
• Technical memory: the first post-delay sell-off has already shaken out many short-term holders, which can make subsequent run-up phases cleaner, but not necessarily less volatile.

The bottom line: this is a bullish, hope-tilted run-up setup built on a real, cash-generating franchise. The FDA decision in FSGS is still binary and dangerous for anyone who holds through the event, but the period between now and April offers traders a straightforward narrative to work with: FILSPARI keeps growing, cash is there, and the market has already reacted once to the delay headline.